Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
申请人:Antel Jochen
公开号:US20050124660A1
公开(公告)日:2005-06-09
The present invention relates to a novel medical use of compounds with CB
1
-receptor activity selected from the group of 4,5-dihydro-1H-pyrazole derivatives, 1H-Imidazole derivatives, thiazole derivatives and/or 1H-1,2,4-triazole-3-carboxamide derivatives, as each defined in the specification, or of a prodrug thereof, a tautomer thereof or a salt thereof, in the manufacture of medicaments for the treatment and/or prophylaxis of CB
1
receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile, as well as in adolescent, patients. Furthermore, the invention pertains to the use of said compounds with CB
1
-receptor activity in combination with lipase inhibitors. Said compounds are particularly suitable in combination with lipase inhibitors in the manufacture of medicaments for the treatment and/or prophylaxis of obesity in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. Preferred lipase inhibitors are orlistat, panclicins, ATL-962 and/or lipstatin.
本发明涉及一种新型医用化合物,该化合物具有CB1受体活性,所述化合物选自4,5-二氢-1H-吡唑衍生物、1H-咪唑衍生物、噻唑衍生物和/或1H-1,2,4-三唑-3-羧酰胺衍生物,如规范中所定义,或其前药、互变异构体或盐,用于制造治疗和/或预防CB1受体相关疾病的药物,适用于青少年患者,以及用于治疗和/或预防青少年和/或成年患者的药物诱导肥胖症。此外,本发明涉及将具有CB1受体活性的化合物与脂肪酶抑制剂结合使用。这些化合物与脂肪酶抑制剂结合使用特别适用于制造用于治疗和/或预防青少年或儿童患者的肥胖症的药物,以及用于治疗和/或预防青少年和/或成年患者的药物诱导肥胖症。优选的脂肪酶抑制剂是奥利司他、泛克立汀、ATL-962和/或脂肪酸盐酶抑制剂。